Justmet Myo Tablet SR is a combination oral medication containing Metformin 500 mg and Myo-Inositol 600 mg, formulated to support glycemic control and metabolic health. Metformin, a biguanide class antihyperglycemic agent, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, making it a first-line therapy for type 2 diabetes mellitus. Myo-Inositol, a naturally occurring carbocyclic sugar, plays a crucial role in insulin signal transduction and cellular function, contributing to improved insulin resistance and metabolic parameters, particularly in conditions such as polycystic ovary syndrome (PCOS) and metabolic syndrome. The sustained-release (SR) formulation of Justmet Myo Tablet ensures a gradual release of active ingredients, promoting better gastrointestinal tolerability and sustained plasma concentrations, thereby enhancing patient compliance and therapeutic efficacy. This combination is particularly beneficial for individuals with insulin resistance, impaired glucose tolerance, or those requiring adjunctive therapy to lifestyle modifications. It is advised to use Justmet Myo Tablet SR under medical supervision, with regular monitoring of blood glucose levels and renal function. Contraindications include known hypersensitivity to components, severe renal impairment, and conditions predisposing to lactic acidosis. Adverse effects may include gastrointestinal disturbances, which are generally mild and transient.